The U.S. Food and Drug Administration (FDA) has escalated its stance against potentially dangerous synthetic compounds, issuing warning letters to seven companies marketing products containing 7-hydroxymitragynine (7-OH). This move highlights significant regulatory concerns and public health risks associated with these concentrated, lab-made substances often misleadingly linked to kratom.
Beyond Natural Kratom: The Rise of Synthetic 7-OH
While trace amounts of 7-OH occur naturally in kratom (Mitragyna speciosa), a Southeast Asian botanical used by an estimated 1.7 million Americans (2021 data), the FDA's action targets a different beast. The warned companies sell products containing synthesized 7-OH in concentrations far exceeding natural levels. These products, found online and in smoke/vape shops and convenience stores, are distinct from traditional kratom leaf or powder.
FDA's Core Concerns: Safety, Legality, and Misleading Marketing
The FDA's warning letters detail critical issues:
-
Illegal Marketing: 7-OH is not lawful in dietary supplements or conventional foods. There are no FDA-approved drugs containing it.
-
Unproven Safety: These products lack FDA evaluation for safety. The agency has received adverse event reports linked to 7-OH.
-
Opioid-Like Effects: 7-OH is reported to have effects similar to opioids, raising significant addiction and safety red flags.
-
Misrepresentation: The FDA and industry stakeholders (like the Natural Products Association - NPA) emphasize that calling these synthetic products "kratom" is highly misleading. Their chemical profile differs drastically from the natural plant.
"Consumers who use 7-OH products are exposing themselves to products that have not been proven safe or effective for any use," the FDA stated unequivocally.
Industry Reactions: Support for Action & Calls for Caution
The FDA's move garnered support from major industry groups concerned about public safety and the reputation of legitimate natural products.
"Based on peer-reviewed research... highly concentrated or semi-synthetic 7-OH products pose significant public health risks and have been falsely marketed as ‘kratom,'" stated Dr. Daniel Fabricant, President & CEO of the NPA. "NPA encourages FDA... to take any necessary steps to swiftly remove them from U.S. commerce."
Unanswered Questions & The Need for Research
Despite the warnings, Dr. Kirsten Smith, a researcher at Johns Hopkins University, cautions that definitive data on the immediate public health risk of current 7-OH products is still emerging. Her unpublished survey research involving over 300 users didn't fully confirm an immediate crisis signal, though she stresses the need for more human pharmacokinetic data.
"We need more... data in humans. But I don’t know if we have a clear danger signal yet," Dr. Smith noted, clarifying she wasn't advocating for a specific regulatory outcome. Her recent co-authored letter in Addiction highlighted concerns about varying product dosages (14mg-25mg) and delivery methods (sublingual, nasal sprays) and their unknown effects.
The Murky Status of Kratom Itself
This action occurs against the backdrop of ongoing regulatory uncertainty surrounding natural kratom. The FDA maintains that kratom is not an approved dietary ingredient, rendering any kratom-containing supplements on the market technically adulterated and illegal. A key industry debate centers on whether kratom was marketed prior to the 1994 DSHEA law, potentially qualifying it as an "old dietary ingredient."
Key Takeaways for Consumers and Industry
-
The FDA is actively targeting synthetic 7-hydroxymitragynine (7-OH) products.
-
These products are illegally marketed, pose unproven safety risks, and exhibit opioid-like effects.
-
They are distinct from natural kratom and their marketing as such is misleading.
-
Consumers should avoid 7-OH products due to the lack of safety evaluation and regulatory approval.
-
Significant research gaps remain regarding the specific risks of these synthetic products.
-
The regulatory future of natural kratom in the US remains unresolved.
Stay Informed on Regulatory Changes
This FDA enforcement action underscores the critical importance of ingredient safety, regulatory compliance, and transparent marketing within the natural products and supplement space. Companies and consumers alike must stay vigilant regarding evolving regulations concerning novel and potentially psychoactive substances.
